Renaissance Capital logo

ACHN News

Fungal infections biotech SCYNEXIS sets terms for $55 million IPO

SCYNEXIS, a biotech developing treatments for life-threatening fungal infections, announced terms for its IPO on Wednesday. The Durham, NC-based company plans to raise $55 million by offering 4.2 million shares at a price range of $12 to $14. At the midpoint of...read more

Drug company Achillion prices below range at $11.50

Achillion Pharmaceuticals, which is Developing novel treatments for infectious diseases, including HIV and Hepatitis C, priced its initial public offering of 4.5 million shares at $11.50, below its proposed $14 to $16 price range, on Wednesday night. Cowen &...read more

Drug developer Achillion Pharmaceuticals announces terms for IPO

Achillion Pharmaceuticals, which is developing treatments for infectious diseases, including HIV and Hepatitis C, announced the terms for its IPO on Friday. The Connecticut-based company plans to offer 4.5 million shares at a range of $14-$16, giving the deal a...read more

Drug developer Achillion files for IPO

Achillion, a developer of novel treatments for infectious diseases, including HIV and Hepatitis C, registered for an initial public offering late Friday night. The New Haven, CT-based company generated $8.5 million in sales for the 2005 fiscal year, but has yet...read more

Archived Headlines